BioMarin Pharmaceutical Inc.
BMRNNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $10.99B
- P/E (TTM)
- 150.67
- Forward P/E
- 303.16
- Dividend yield
- -
- 52-week range
- $49.26$70.98
- Volume (live)
- -
- Avg. volume (3M)
- 2.32M
BioMarin Pharmaceutical (BMRN) Stock Price & Financial Analysis
BioMarin Pharmaceutical Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $55.02 - $56.91 |
|---|---|
| 52-Week High | $70.98 |
| 52-Week Low | $49.26 |
| Open | $55.40 |
| Volume (last close) | 2.40M |
| Average Volume (3M) | 2.32M |
| Revenue (TTM) | 3.41B |
|---|---|
| Net Income (TTM) | 72.97M |
| Free Cash Flow (TTM) | 730.51M |
| EPS (TTM) | $0.37 |
| Profit Margin | 2.14% |
| Operating Margin | 8.02% |
| Return on Equity (ROE) | 1.15% |
| Debt to Equity | 0.66 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 10.99B |
|---|---|
| Shares Outstanding | 194.15M |
| P/E Ratio (TTM) | 150.67 |
| Forward P/E | 303.16 |
| Price to Sales (P/S) | 3.23 |
| Price to Book (P/B) | 1.74 |
| EV/EBITDA | 37.13 |
| 50-Day MA | $62.52 |
|---|---|
| 200-Day MA | $58.52 |
| 1-Year Change | +3.81% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
BioMarin Pharmaceutical at a Glance
As of the Oct 22, 2026 close, BioMarin Pharmaceutical (BMRN) has a market capitalization of $10.99B. The stock trades at 150.7× trailing earnings, 303.2× forward earnings and 3.2× sales. Over the trailing twelve months it earned $72.97M on revenue of $3.41B (a 2.1% profit margin) and generated $730.51M of free cash flow. Revenue grew 11.2% year over year.
As of its latest reported balance sheet, it holds $874.00M in cash and securities against $4.20B of debt, a net debt position of $3.33B.
BioMarin Pharmaceutical does not currently pay a dividend.
The share price is up 3.8% over the past year. At $56.63 (the Oct 22, 2026 close) it sits within its 52-week range of $49.26 to $70.98, below its 200-day moving average of $58.52.
Based on 26 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $93.05, 64.3% above the Oct 22, 2026 close.
Frequently Asked Questions About BioMarin Pharmaceutical
What is the current stock price for BMRN?
As of the Oct 22, 2026 close, BMRN stock trades at $56.63. The 52-week range is $49.26–$70.98, with a day range of $55.02–$56.91.
What is the P/E ratio for BMRN?
As of the Oct 22, 2026 close, BioMarin Pharmaceutical's trailing twelve-month (TTM) P/E ratio is 150.7, meaning investors pay $150.7 for every $1 of annual earnings. The forward P/E is 303.2, reflecting analyst expectations for future earnings. BioMarin Pharmaceutical operates in the Healthcare sector.
Does BMRN pay dividends?
BioMarin Pharmaceutical does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for BMRN?
Based on ratings from 26 professional analysts over the last 90 days, the consensus for BMRN is Buy. The average 12-month price target is $93.05, a 64.3% upside from the Oct 22, 2026 close of $56.63.
What is the market cap of BMRN?
As of the Oct 22, 2026 close, BioMarin Pharmaceutical's market capitalization is $10.99B, classifying it as a large-cap company. BioMarin Pharmaceutical operates in the Healthcare sector within the Biotechnology industry.